Traded May 13 – May 14, 2025 · largest single transaction ~$36K
Show all 2 transactions
May 14, 2025~$14K · 7,730 sh @ $1.86
DetailsOfficial recordMay 13, 2025~$36K · 20K sh @ $1.82
DetailsOfficial record
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
APUS · NYSE · Pharmaceutical Preparations
Apimeds Pharmaceuticals US (APUS) · oqro.io/stocks/APUS · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$1.60−0.14 (−8.05%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
Traded May 13 – May 14, 2025 · largest single transaction ~$36K
May 14, 2025~$14K · 7,730 sh @ $1.86
DetailsOfficial recordMay 13, 2025~$36K · 20K sh @ $1.82
DetailsOfficial recordInsider buying
Traded May 12, 2025 · filed 2 days later
A major shareholder of Apimeds Pharmaceuticals US paid $2M out of pocket for Apimeds Pharmaceuticals US shares. 2 other people at Apimeds Pharmaceuticals US bought some too, in the same month. Shares held went up 34% with this purchase.
Insider buying
Traded May 12, 2025 · filed 2 days later
An Apimeds Pharmaceuticals US director paid $57K out of pocket for Apimeds Pharmaceuticals US shares. 2 other people at Apimeds Pharmaceuticals US bought some too, in the same month.
No earnings release (8-K Item 2.02) is on file for APUS, so its insider trades cannot be placed against one.